Previous close | 23.50 |
Open | 18.50 |
Bid | 16.85 |
Ask | 17.50 |
Strike | 165.00 |
Expiry date | 2025-12-19 |
Day's range | 18.50 - 18.96 |
Contract range | N/A |
Volume | |
Open interest | 111 |
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug Humira. AbbVie said it expects adjusted earnings in 2024 of between $11.13 and $11.33 a share, up from previous guidance of $10.97 to $11.17 a share. Analysts surveyed by FactSet were expecting the biopharmaceutical company to post full-year earnings of $11.12 a share.